Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Cash: 2016-2025

Historic Change in Cash for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to -$55.0 million.

  • Tg Therapeutics' Change in Cash fell 148.74% to -$55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.7 million, marking a year-over-year decrease of 370.86%. This contributed to the annual value of $87.0 million for FY2024, which is 1029.31% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' Change in Cash is -$55.0 million, which was down 1,735.01% from -$3.0 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Change in Cash peaked at $112.9 million during Q3 2024, and registered a low of -$113.2 million during Q1 2022.
  • Its 3-year average for Change in Cash is -$2.6 million, with a median of -$15.9 million in 2024.
  • Its Change in Cash has fluctuated over the past 5 years, first slumped by 1,083.02% in 2021, then surged by 244.84% in 2023.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Change in Cash stood at -$27.6 million in 2021, then soared by 72.66% to -$7.6 million in 2022, then plummeted by 667.56% to -$58.0 million in 2023, then skyrocketed by 72.53% to -$15.9 million in 2024, then crashed by 148.74% to -$55.0 million in 2025.
  • Its last three reported values are -$55.0 million in Q3 2025, -$3.0 million for Q2 2025, and -$47.8 million during Q1 2025.